Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Relapsed/Refractory CTCL
NCT07535710Phase 2Not yet recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aclarubicin in cutaneous T-cell lymphoma (CTCL), Sézary syndrome (SS), sponsored by Shanghai Jiao Tong University School of Medicine. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
aclarubicin
03
Conditions
cutaneous T-cell lymphoma (CTCL)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT07535710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07535710.